BriaCell Therapeutics Corp.’s (OTCQB: BCTXF) (TSX.V: BCT) Development of Personalized Immunotherapy Focuses on Advanced Breast Cancer
Experienced management has been involved in over 10 drug approvals Developing Bria-OTS, the first off-the-shelf personalized immunotherapy targeting advanced breast cancer Impressive results in two proof-of-concept clinical trials revealed rapid response rate, repeated following re-treatment, and excellent safety profile for Bria-IMT, BriaCell’s lead clinical candidate Unmet medical needs of advanced breast cancer estimated between $1 billion and $5 billion, depending on treatment stage Developing Bria-OTS along with BriaDX, a companion diagnostic test, offering the ability to match and treat over 99 percent of the patient population with off-the-shelf personalized immunotherapy BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), an immuno-oncology focused…